Salix Pharmaceuticals, Ltd.
MarketLine (a Datamonitor Company)
08 Apr 2014
Available for Immediate Download
Salix Pharmaceuticals, Ltd. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Salix Pharmaceuticals, Ltd. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Salix Pharmaceuticals, Ltd. in the form of a SWOT analysis - An in-depth view of the business model of Salix Pharmaceuticals, Ltd. including a breakdown and examination of key business segments - Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Salix Pharmaceuticals, Ltd. - Intelligence on Salix Pharmaceuticals, Ltd.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Salix Pharmaceuticals, Ltd., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Salix Pharmaceuticals (Salix or 'the company') is a specialty pharmaceutical company engaged in the development and marketing of prescription pharmaceutical products for the treatment of gastrointestinal diseases. The company's marketed drugs include Xifaxan, Osmoprep, and Metozolv ODT. Salix primarily operates in the US, where it is headquartered in Raleigh, North Carolina. It employed about 525 people as of December 31, 2012. The company recorded revenues of $735.4 million during the financial year ended December 2012 (FY2012), an increase of 36.1% over FY2011. The operating profit of the company was $172.1 million in FY2012, an increase of 48.5% over FY2011. The net profit was $64.2 million in FY2012, a decrease of 26.5% over FY2011. Reasons to Purchase: - Gain understanding of Salix Pharmaceuticals, Ltd. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Salix Pharmaceuticals, Ltd. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Salix Pharmaceuticals, Ltd.’s business structure, strategy and prospects